Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INOvation-1 in pulmonary arterial hypertension
NL-OMON46327Phase 3Active, not recruiting
- Sponsor
- Bellerophon Therapeutics
- Start
- Sep 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nitric oxide in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Bellerophon Therapeutics. Primary endpoints: Placebo-adjusted change in 6-minute walk distance and Incidence of adverse events and serious adverse events. Started Sep 2017; status: active, not recruiting.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON46327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46327.